U.S. Energy Services Stock News

eXp World Holdings (EXPI) opened Q1 2026 with revenue of US$1.0 billion and a basic EPS loss of US$0.03, alongside net income from ongoing operations that was a loss of US$5.1 million. This sets a clear snapshot of a high volume but still loss making quarter. Over recent periods the company has seen quarterly revenue move from US$954.9 million in Q1 2025 to US$1.0 billion in Q1 2026. Basic EPS has ranged between a loss of US$0.08 in Q4 2025 and a small profit of US$0.02 in Q3 2025, giving...

Wondering whether Alexandria Real Estate Equities is priced attractively or still too expensive at around US$46.50? This article walks through what the current share price might be implying about the stock's underlying value. The stock has risen 6.2% over the past week and 9.1% over the past month, yet is still down 5.0% year to date and has declined 31.5% over the last year, 53.7% over three years and 66.8% over five years, which can change how investors think about both risk and potential...

Everspin Technologies (MRAM) has moved into the spotlight after securing a US$40 million multi year defense subcontract linked to U.S. aerospace and defense programs, along with reporting Q1 results that topped revenue expectations. See our latest analysis for Everspin Technologies. The stock has attracted fresh attention, with a 30 day share price return of 328.95% and a very large 1 year total shareholder return. Investors are reacting to the US$40 million defense subcontract, the Q1 beat...

Eos Energy Enterprises (NasdaqCM:EOSE) and Cerberus Capital Management launched Frontier Power USA, a joint venture focused on large-scale, American-made long-duration energy storage projects. The venture is supported by major equity commitments and a multi-year 2 GWh capacity reservation agreement tied to Eos’s battery systems. Eos announced a substantial rights offering to fund its share of the joint venture and reported record quarterly production from its manufacturing operations. Eos...

Babcock & Wilcox Enterprises (BW) has reported Q1 2026 results with revenue of US$214.4 million and a basic EPS loss of US$0.62, setting a clear marker for how the business is currently trading. Over recent quarters the company has seen revenue move from US$155.8 million in Q1 2025 to US$138.8 million in Q4 2025 and then to US$214.4 million in Q1 2026. Basic EPS shifted from a loss of US$0.18 in Q1 2025 to a loss of US$0.12 in Q4 2025 and then to a loss of US$0.62 this quarter, giving...

In the first quarter of 2026, Constellium SE reported higher sales of US$2,461 million and net income of US$199 million, alongside completing a multi-year share repurchase program totaling 14,779,353 shares for US$221.14 million under its February 2024 authorization. This combination of stronger profitability and substantial buybacks has prompted several research firms to upgrade their outlook on Constellium, highlighting improved earnings expectations and a more shareholder-focused capital...

Camtek (NasdaqGM:CAMT) reports exceptionally strong incoming orders tied to advanced semiconductor packaging and AI-driven inspection. The company highlights recent AI-focused deals, including its acquisition of Visual Layer, as a key part of its technology roadmap. Management signals an expectation for more than 25% revenue growth in the second half of 2026, pointing to a step change in demand. For investors tracking NasdaqGM:CAMT, the fresh orders and AI-focused investments add a new...

Coherus Oncology (CHRS) opened Q1 2026 with total revenue of US$12.3 million and a basic EPS loss of US$0.27, presenting a clear picture of a business still in investment mode. Over recent quarters the company reported revenue of US$7.7 million in Q4 2024, US$7.6 million in Q1 2025, US$10.3 million in Q2 2025, US$12.7 million in Q4 2025, and US$12.3 million in the latest quarter. Over the same period, basic EPS losses moved from US$0.40 in Q4 2024 to US$0.41 in Q1 2025, then around US$0.38...

Green Brick Partners, Inc. has restated its 2023–2025 financial statements due to revenue recognition errors and reported weaker first-quarter 2026 results, with net income falling to US$60.95 million and diluted EPS from continuing operations at US$1.39. The company also disclosed a material weakness in internal controls over financial reporting while completing a share repurchase program totaling 1,500,828 shares for US$90.13 million, highlighting both governance concerns and continued...

flyExclusive (FLYX) opened Q1 2026 with total revenue of US$96.4 million and a basic EPS loss of US$0.17, alongside a net income loss of US$7.9 million. These figures put fresh numbers behind a business that is still working through loss-making quarters. The company reported revenue of US$91.4 million in Q4 2024, US$88.1 million in Q1 2025, and US$96.4 million in Q1 2026, while quarterly EPS has remained in loss territory between US$0.17 and US$0.30 over that period. This has kept margins...

Accendra Health (ACH) has kicked off Q1 2026 with revenue of US$627.8 million and a reported loss of US$6.5 million, translating to EPS of US$0.08, while trailing twelve month revenue sits at about US$2.7 billion with a loss of US$105.3 million and EPS of US$1.37. Over recent quarters the company has seen revenue move between US$673.9 million in Q1 2025 and US$709.0 million in Q4 2025, alongside EPS shifting from a loss of US$0.05 in Q1 2025 to a loss of US$0.12 in Q4 2025, before the latest...

Wondering if Essent Group at US$60.87 is still a good deal or already pricing in the story? This article breaks down what the current share price might be implying about value. The stock has been relatively steady, with returns of 1.2% over the past week, 0.6% over the past month, a decline of 5.9% year to date, and a 4.6% return over the last year. The 3 year and 5 year returns sit at 48.5% and 40.5% respectively. Recent coverage around Essent Group has focused on its position within the...

Recent trading in Ocular Therapeutix (OCUL) has drawn attention, with the stock declining over the past week while remaining higher over the past month and over the past year. See our latest analysis for Ocular Therapeutix. Taking a step back, the stock’s recent pullback sits against a mixed backdrop, with the share price down year to date but a 1 year total shareholder return of 30.86%, suggesting earlier optimism has cooled near the current US$9.16 level. If you are comparing Ocular...

nLIGHT (LASR) drew investor attention after first quarter 2026 results topped analyst expectations, with revenue of US$80.18 million, a shift to positive net income, and management issuing upbeat guidance for the next quarter. See our latest analysis for nLIGHT. nLIGHT’s share price has been on a strong run, with a 7 day share price return of 25.18%, a 90 day share price return of 52.83% and a year to date share price return of 118.43%. The 1 year total shareholder return is also very large,...

Halozyme Therapeutics (HALO) opened 2026 with Q1 revenue of US$376.7 million and basic EPS of US$1.27, against a backdrop where trailing 12 month revenue sits at about US$1.5 billion and EPS at US$2.94. Over recent quarters, the company has seen revenue move from US$298.0 million in Q4 2024 to US$264.9 million in Q1 2025, then to US$325.7 million in Q2 2025, US$354.3 million in Q3 2025, US$451.8 million in Q4 2025, before the latest US$376.7 million print. Quarterly basic EPS has ranged from...

Paycom Software (NYSE:PAYC) is sponsoring the National Duals Invitational, a new collegiate wrestling event with a $1 million prize pool. The sponsorship links Paycom to a high-profile college sports platform, extending its visibility beyond its payroll and HR software business. This move is intended to deepen community engagement and reach student athletes, fans, and future workforce participants. For investors watching NYSE:PAYC, this sponsorship adds a fresh angle to a story often...

Tuya (NYSE:TUYA) heads into its Q1 2026 reporting cycle with recent numbers that give investors clear reference points, with Q4 2025 revenue at US$84.5 million and basic EPS of US$0.03 backed by trailing twelve month revenue of US$321.8 million and EPS of US$0.09 versus prior year figures that included smaller profits and an earlier loss. Over the past six quarters, revenue has moved from US$81.6 million in Q3 2024 to US$82.1 million in Q4 2024 and then to US$84.5 million by Q4 2025, while...

Vinci Compass Investments (NasdaqGS:VINP) opened 2026 with Q1 revenue of R$274.9 million and Basic EPS of R$1.57, set against trailing twelve month revenue of R$1.0 billion and Basic EPS of R$4.13 that sit alongside a net margin of 26% and a 105.4% year over year earnings improvement influenced by a R$96.1 million one off gain. Over the past six reported quarters, revenue has ranged from R$234.7 million in Q1 2025 to R$274.9 million in Q1 2026, while quarterly Basic EPS has moved between...

The market for Solstice Advanced Materials, Inc.'s ( NASDAQ:SOLS ) shares didn't move much after it posted weak...

The market for Solventum Corporation's ( NYSE:SOLV ) stock was strong after it released a healthy earnings report last...

The latest earnings report from Montauk Renewables, Inc. ( NASDAQ:MNTK ) disappointed investors. We did some digging...

Celebrations may be in order for NewAmsterdam Pharma Company N.V. ( NASDAQ:NAMS ) shareholders, with the analysts...

Celebrations may be in order for Janux Therapeutics, Inc. ( NASDAQ:JANX ) shareholders, with the analysts delivering a...

Market forces rained on the parade of GeneDx Holdings Corp. ( NASDAQ:WGS ) shareholders today, when the analysts...